Nanobiotix to present at the Jefferies and UBS conferences in London on November 16 and 17
The press release published on November 9, 2026 relates to the financial calendar and not to a new strategic announcement. It sets the dates on which the management of the Paris-based biotech will address the financial community during the month.
Jefferies on November 16, UBS the following day, in London
The first event is scheduled for November 16, 2026, in London, as part of the Jefferies Global Healthcare Conference. The presentation is scheduled for 8:30 a.m. Eastern Time, or 1:30 p.m. GMT.
It will be delivered by Laurent Levy, Chief Executive Officer, and Arnd Christ, Chief Financial Officer. On November 17, 2026, management will then take part in the UBS Global Biopharma Conference, also held in the British capital.
Three nanotechnology platforms and more than 30 patents
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The press release recalls the positioning claimed by the company: a biotech at an advanced clinical stage developing nanotherapeutic approaches designed to expand treatment options for patients with cancer and other major diseases.
Nanobiotix states that it holds more than 30 "umbrella" patents associated with three nanotechnology platforms, applied to oncology, bioavailability and biodistribution, as well as to central nervous system disorders.
Founded in 2003 and headquartered in Paris, the company has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020. It notably has a subsidiary in Cambridge, Massachusetts.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
